These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31391551)

  • 1. PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers.
    Zhong Z; Sepramaniam S; Chew XH; Wood K; Lee MA; Madan B; Virshup DM
    Oncogene; 2019 Oct; 38(40):6662-6677. PubMed ID: 31391551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study.
    Huang L; Yang H; Chen K; Yuan J; Li J; Dai G; Gu M; Shi Y
    Clin Transl Med; 2023 Dec; 13(12):e1500. PubMed ID: 38037549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma.
    Jiang X; Hao HX; Growney JD; Woolfenden S; Bottiglio C; Ng N; Lu B; Hsieh MH; Bagdasarian L; Meyer R; Smith TR; Avello M; Charlat O; Xie Y; Porter JA; Pan S; Liu J; McLaughlin ME; Cong F
    Proc Natl Acad Sci U S A; 2013 Jul; 110(31):12649-54. PubMed ID: 23847203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models.
    Diersch S; Wenzel P; Szameitat M; Eser P; Paul MC; Seidler B; Eser S; Messer M; Reichert M; Pagel P; Esposito I; Schmid RM; Saur D; Schneider G
    Oncotarget; 2013 Feb; 4(2):277-88. PubMed ID: 23470560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
    Tzeng HE; Yang L; Chen K; Wang Y; Liu YR; Pan SL; Gaur S; Hu S; Yen Y
    Oncotarget; 2015 May; 6(13):11061-73. PubMed ID: 25857298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Porcupine Inhibition Disrupts Mitochondrial Function and Homeostasis in WNT Ligand-Addicted Pancreatic Cancer.
    Aguilera KY; Le T; Riahi R; Lay AR; Hinz S; Saadat EA; Vashisht AA; Wohlschlegel J; Donahue TR; Radu CG; Dawson DW
    Mol Cancer Ther; 2022 Jun; 21(6):936-947. PubMed ID: 35313331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
    Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
    Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphoglycerate Mutase 1 (PGAM1) Promotes Pancreatic Ductal Adenocarcinoma (PDAC) Metastasis by Acting as a Novel Downstream Target of the PI3K/Akt/mTOR Pathway.
    Liu X; Tan X; Liu P; Wu Y; Qian S; Zhang X
    Oncol Res; 2018 Aug; 26(7):1123-1131. PubMed ID: 29386088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deficient Rnf43 potentiates hyperactive Kras-mediated pancreatic preneoplasia initiation and malignant transformation.
    Zhou X; Sun Z; Zhang M; Qu X; Yang S; Wang L; Jing Y; Li L; Deng W; Liu F; Di J; Chen J; Wu J; Zhang H
    Animal Model Exp Med; 2022 Feb; 5(1):61-71. PubMed ID: 35229994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
    Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
    Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer.
    Milton CK; Self AJ; Clarke PA; Banerji U; Piccioni F; Root DE; Whittaker SR
    Mol Cancer Ther; 2020 Jul; 19(7):1423-1435. PubMed ID: 32371585
    [No Abstract]   [Full Text] [Related]  

  • 12. Novel PORCN inhibitor WHN-88 targets Wnt/β-catenin pathway and prevents the growth of Wnt-driven cancers.
    Yang Q; Qin T; An T; Wu H; Xu G; Xiang J; Lei K; Zhang S; Xia J; Su G; Wang D; Xue M; Kong L; Zhang W; Wu S; Li Y
    Eur J Pharmacol; 2023 Apr; 945():175628. PubMed ID: 36858339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer.
    Ning C; Liang M; Liu S; Wang G; Edwards H; Xia Y; Polin L; Dyson G; Taub JW; Mohammad RM; Azmi AS; Zhao L; Ge Y
    Oncotarget; 2017 Jul; 8(27):44295-44311. PubMed ID: 28574828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer.
    De Santis MC; Gozzelino L; Margaria JP; Costamagna A; Ratto E; Gulluni F; Di Gregorio E; Mina E; Lorito N; Bacci M; Lattanzio R; Sala G; Cappello P; Novelli F; Giovannetti E; Vicentini C; Andreani S; Delfino P; Corbo V; Scarpa A; Porporato PE; Morandi A; Hirsch E; Martini M
    Gut; 2023 Feb; 72(2):360-371. PubMed ID: 35623884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A p300/GATA6 axis determines differentiation and Wnt dependency in pancreatic cancer models.
    Zhong Z; Harmston N; Wood KC; Madan B; Virshup DM
    J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35536676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptome data-based status of PI3K/AKT/mTOR pathway indicates heterogeneity and immune modulation in patients with pancreatic ductal adenocarcinoma.
    Xie P; Tan SY; Li HF; Tang HD; Zhou JH
    J Gene Med; 2024 Jan; 26(1):e3570. PubMed ID: 37482968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer.
    Totiger TM; Srinivasan S; Jala VR; Lamichhane P; Dosch AR; Gaidarski AA; Joshi C; Rangappa S; Castellanos J; Vemula PK; Chen X; Kwon D; Kashikar N; VanSaun M; Merchant NB; Nagathihalli NS
    Mol Cancer Ther; 2019 Feb; 18(2):301-311. PubMed ID: 30404927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
    Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
    Burmi RS; Maginn EN; Gabra H; Stronach EA; Wasan HS
    Cancer Biol Ther; 2019; 20(1):21-30. PubMed ID: 30261145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.
    Venkannagari S; Fiskus W; Peth K; Atadja P; Hidalgo M; Maitra A; Bhalla KN
    Oncotarget; 2012 Nov; 3(11):1416-27. PubMed ID: 23232026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.